2023 is shaping up to be a major year for stem cell stocks. Scientists have been researching stem cell therapies for many years, and this research is now starting to pay dividends. Although the technology is still in its early stages, a handful of companies have already emerged as major players in stem cell treatments. With the landscape of stem cell stocks expected to grow significantly in the years to come, it is important to keep track of these companies and their progress. As of early 2023, these are the 10 biggest NASDAQ companies working in the stem cell space. Number one on the list is Celularity, Inc., a biotechnology company focused on breakthrough stem cell therapies. It’s clinical-stage products treat a variety of conditions and diseases, including solid tumors, hematologic malignancies, immune-mediated diseases, and allogeneic stem cell transplantation. Celularity is looking to leverage its technology to revolutionize the landscape of cell therapy. Next on the list is Notable Biosciences. This company is primarily focused on uncovering and developing stem cell programs to treat various diseases. It is using regenerative medicine to target conditions such as chronic conditions and genetic disorders. Third on the list is Atara Biotherapeutics. This company is focused on developing treatments for serious illnesses using genetically engineered T-cells. It is developing off-the-shelf, T-cell-based therapies for cancers, autoimmune diseases, and other diseases. Fourth on the list is Pluristem Therapeutics, Inc. It is a biotherapy company utilizing the therapeutic potential of adult mesenchymal stem cells for the treatment of various conditions. Its products are specifically designed to target areas with limited regenerative capability, such as vascular and musculoskeletal diseases. Fifth on the list is Bluebird Bio. This company is working in the gene therapy field, delivering potential treatments for people preparing serious conditions. Its gene therapies leverage blocked pathways to potentially repair and replace damaged cells. Sixth on the list is Adaptive Biotechnologies. This company seeks to unlock the power of the immune system by combining genomics and data science. It primarily develops tumor-infiltrating lymphocytes, a type of cell isolated from human tumors. Seventh on the list is Mesoblast, Limited. This company is dedicated to the research and development of regenerative medicine. Its pipeline of treatments leverages its allogeneic mesenchymal stem cell technology to address diseases in which inflammation is a major factor. Eighth on the list is Intellia Therapeutics. This company isfocused on developing one-time, targeted gene editing therapies using CRISPR-Cas9 technology. Its products are designed to treat highly devastating conditions such as genetic disorders. Ninth on the list is Livzon Pharmaceutical Group. This company is based in China and is dedicated to developing treatments using stem cell-based technologies. Its research is focused on treating a variety of conditions, including mitochondrial diseases, autoimmunity, and organ transplantation. The 10th and last company on the list is Pluristem Therapeutics, Inc., a biotechnology company based in Israel. It ismainly focused on regenerative medicine and cell therapiesto treat cardiovascular and orthopaedic diseases, as well as more serious conditions such as cancer. Collectively, the advancements these 10 companies are making in the field of stem cell research could revolutionize the healthcare industry in years to come. Although the technology is still relatively nascent, the potential for stem cell treatments to treat a wide range of diseases is becoming ever morereal. These companies are undoubtedly ones to watch in 2023 and beyond.